Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Employees - 362, CEO - Dr. Eric Venker M.D., Pharm.D., Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 19.09, Piotroski Score(max is 10): 1, Working Capital: $698887000, Total Assets: $776222000, Retained Earnings: $-1239523000, EBIT: -426859000, Total Liabilities: $68775000, Revenue: $160000

AryaFin Target Price - $4.7 - Current Price $ - Analyst Target Price $